Entrada Therapeutics, Inc. (TRDA) will announce topline results from Cohort 1 of its phase 1/2 clinical study of ENTR-601-44 in Duchenne muscular dystrophy on Thursday, May 7, 2026.
Duchenne muscular dystrophy is a rare disease caused by mutations in the DMD gene, which encodes for the dystrophin protein essential to maintaining the structural integrity and function of muscle cells.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.